Menu
Recruiting NCT06668805

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

Phase II Interventional Noonan Syndrome

For patients and families

In plain language

Fill the application

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Vosoritide Injection.
Who it may be relevant to
Registry conditions: Noonan Syndrome. Basic parameters: 3 years — 11 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Australia, Canada, France, Germany +2
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase 2, Randomized, Multicenter, Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

Overview

The purpose of this study in children with Noonan syndrome is to evaluate the effect of 3 doses of vosoritide on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up to FAH.

Detailed description

This is a Phase 2, randomized, multicenter, study of vosoritide in children with Noonan syndrome who have inadequate growth during or after human growth hormone (hGH) treatment. The study is intended to characterize the short-term efficacy and safety of 3 dosing regimens of vosoritide. The efficacy and safety of the vosoritide therapeutic dose will be further evaluated, and an analysis of the impact of vosoritide on final adult height (FAH).

Interventions

  • Drug Vosoritide Injection
    Modified recombinant human C-type natriuretic peptide Vosoritide

Primary outcome measures

  • Change from baseline in Annualized Growth Velocity (AGV) [Time frame: At 6 months]
Secondary outcome measures (12)
  • Incidence of treatment-emergent adverse events [Time frame: Until the end of the study, up to 15 years]
  • Incidence of new diagnosis of hypertrophic cardiomyopathy in children with Noonan syndrome [Time frame: Every 12 months through the end of the study, up to 15 years]
  • Incidence of cardiac conditions requiring discontinuation of study treatment [Time frame: Every 12 months through the end of the study, up to 15 years]
  • Change from baseline in height [Time frame: Every 6 months through the end of the study, up to 15 years]
  • Change from baseline in height Z-score [Time frame: Every 6 months through the end of the study, up to 15 years]
  • Change from baseline in 12-month interval AGV [Time frame: Until the end of the study, up to 15 years]
  • Change from baseline in upper to lower body segment ratio [Time frame: Until the end of the study, up to 15 years]
  • Change from baseline in arm span to height ratio [Time frame: Until the end of the study, up to 15 years]
  • Change from baseline in height up to Final Adult Height (FAH) [Time frame: Every 6 months through the end of the study, up to 15 years]
  • Change from baseline in height Z-score up to FAH [Time frame: Every 6 months through the end of the study, up to 15 years]
  • 12-month interval AGV summarized by age and sex up to FAH [Time frame: Every 12 months through the end of the study, up to 15 years]
  • Tanner stage over the course of the study [Time frame: Every 6 months through the end of the study, up to 15 years]

Eligibility criteria

Inclusion criteria

  • Participants must be ≥ 3 years old, and < 11 years old (females) or < 12 years old (males), at the time of signing the informed consent form
  • A genetically confirmed diagnosis of Turner syndrome, SHOX deficiency or Noonan syndrome.
  • A height assessment corresponding to a height Z-score of ≤ -1.28 SDs (below the 10th percentile for height) in reference to the general population of the same age and sex.
  • Tanner Stage 1, at time of signing the ICF.
  • Previous or current hGH treatment for short stature associated with their condition.
  • Inadequate growth confirmed with an AGV that is less than age- and sex-matched average stature AGV determined using median heights from CDC growth charts

Exclusion criteria

  • Participants with Turner syndrome known to have Y-chromosome material unless they have undergone gonadectomy and have fully external female genitalia.
  • Diagnosis of systemic disease or condition that may cause short stature other than Turner syndrome, SHOX deficiency, or Noonan syndrome, eg, renal, neoplastic, pulmonary, cardiac, gastrointestinal, immunologic and metabolic disease.
  • Bone age advanced beyond chronological age by more than 2 years.
  • Uncorrected congenital heart disease which places the participant at increased risk of an adverse cardiac outcome in the setting of hypotension,
  • Have an unstable condition likely to require surgical intervention during the study.
  • Evidence of decreased growth velocity (AGV < 1.5 cm/year) as assessed over a period of at least 6 months and growth plate closure assessed using bilateral lower extremity X-rays.
  • Previous limb-lengthening surgery, or planned or expected to have limb lengthening surgery during the study period.
  • Planned or expected bone-related surgery (ie, surgery involving disruption of bone cortex, excluding tooth extraction), during the study period.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

United States · 22 centers
  • Childrens Hospital Los Angeles — Los Angeles
  • Children's Hospital of Orange County Main Campus - Orange — Orange
  • Children's Hospital Colorado — Aurora
  • Nemours Children's Hospital, Delaware (Alfred I. Dupont Hospital for Children) — Wilmington
  • Children's National Medical Center — Washington D.C.
  • Nicklaus Children's Hospital — Miami
  • Emory University School of Medicine — Atlanta
  • St. Luke's Children's Endocrinology and Diabetes — Boise
  • … and 14 more centers
France · 5 centers
  • Hôpital de la Timone — Marseille
  • Angers University Hospital Center — Angers
  • CHU de Toulouse - Hôpital des Enfants — Toulouse
  • South Paris University Hospitals - Bicetre Hospital — Le Kremlin-Bicêtre
  • Hôpital Robert-Debré — Paris
Australia · 3 centers
  • Royal North Shore Hospital — Saint Leonards
  • Childrens Health Queensland Hospital and Health Service — South Brisbane
  • Murdoch Children's Research Institute — Parkville
Italy · 3 centers
  • Azienda Ospedaliero Universitaria - Ospedale Pediatrico Meyer — Florence
  • IRCCS Istituto Giannina Gaslini — Genova
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma
Canada · 1 center
  • M.A.G.I.C. Clinic — Calgary
Germany · 1 center
  • Universitätsklinikum des Saarlandes — Homburg
Spain · 1 center
  • Central University Hospital of Asturias — Oviedo

Identifiers

NCT: NCT06668805 · 111-211

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗